Clinical trial
A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
NCT01573572 is registered in ClinicalTrials.gov with Bausch & Lomb Incorporated as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IV, Open Label, Multi-center Study to Assess the Effect of Intravitreal Injections of Macugen (Pegaptanib Sodium Injection) Administered Every 6 Weeks for 48 Weeks on the Corneal Endothelium.
- Lead sponsor
- Bausch & Lomb Incorporated
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- April 22, 2010
- Completion date
- November 14, 2019
- Enrollment
- 131 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
age-related macular degeneration, diabetic macular edema, retinal vein occlusion